Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
Ori Gutwerg, SVP, GENERICS at ANI PHARMACEUTICALS INC (NASDAQ:ANIP), sold 5,873 shares of common stock on August 12, 2025, for approximately $508,190. The stock has shown remarkable strength recently, surging over 30% in the past week and currently trading near its 52-week high of $90.23.
The shares were sold in multiple transactions at prices ranging from $86.50 to $86.79. The weighted average sales price was $86.53. Following the transaction, Gutwerg directly owns 84,024 shares of ANI PHARMACEUTICALS INC, representing a stake in the $1.81 billion pharmaceutical company. According to InvestingPro analysis, the stock is currently showing overbought signals, with 15+ additional real-time insights available to subscribers.
In other recent news, ANI Pharmaceuticals reported robust financial results for the second quarter of 2025, surpassing market expectations. The company achieved an adjusted non-GAAP earnings per share of $1.80, exceeding the FactSet consensus estimate of $1.41. Revenue for the quarter reached $211.4 million, beating the forecast of $187.34 million. Additionally, Cortrophin Gel revenue was a standout, hitting $81.6 million, which represents a 66% year-over-year growth and a 54% increase from the previous quarter. Following these strong results, ANI Pharmaceuticals raised its guidance for revenue, adjusted EBITDA, and EPS.
In response to this performance, H.C. Wainwright raised its price target for ANI Pharmaceuticals to $93 from $84, maintaining a Buy rating. Similarly, Truist Securities increased its price target to $77 from $65, while keeping a Hold rating. These adjustments reflect the analysts’ positive outlook on the company’s recent achievements. The strong performance of the Cortrophin product line was a key factor in these revised targets, as noted by both firms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.